A new subscription payment system, designed in the UK to encourage pharmaceutical manufacturers to develop new antibiotics, has led to the draft approval by NICE of two new drugs. According to the BBC, the innovative payment arrangement will involve a fixed annual fee rather than individual payments.
The increasing problem of microbe resistance to existing antibiotics has emphasised the need for the development of new antibiotics capable of curing patients whose conditions have proved resistant to other forms of treatment.
The two new drugs, cefiderocol and ceftazidime-avbactam, can be used to tackle urinary tract infections, sepsis and pneumonia where other antibiotics have failed and should be available through the NHS soon.
The director of NHS commercial medicines is reported as saying, “this is an important step in our world-leading approach to incentivise innovation in antimicrobial drugs and the battle against drug-resistant infections.”
Medical negligence compensation
If you or a family member have been the victim of negligent medical care, contact Glynns Solicitors, specialists in medical negligence law, to talk to an experienced lawyer about the suitability of making a claim for compensation.
Please call us on 0800 234 3300 (or from a mobile 01275 334030) or complete our Online Enquiry Form.
Share Article With:
|
|
|
|
|
|
